MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates [Yahoo! Finance]
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $73.00. They now have a "buy" rating on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target raised by analysts at Needham & Company LLC from $62.00 to $66.00. They now have a "buy" rating on the stock.
Form 8-K MoonLake Immunotherapeut For: Mar 31
Form 4 MoonLake Immunotherapeut For: Feb 27 Filed by: Santos da Silva Jorge
Form 4 MoonLake Immunotherapeut For: Feb 27 Filed by: Reich Kristian
Form 4 MoonLake Immunotherapeut For: Feb 27 Filed by: Bodenstedt Matthias
Form 10-K MoonLake Immunotherapeut For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.